What’s Heron Therapeutics Inc (HRTX) Upside After Today’s Huge Increase?

September 17, 2017 - By reb123z

The stock of Heron Therapeutics Inc (NASDAQ:HRTX) is a huge mover today! The stock increased 5.12% or $0.75 on September 15, reaching $15.4. About 1.20 million shares traded or 142.29% up from the average. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 20.92% since September 17, 2016 and is downtrending. It has underperformed by 37.62% the S&P500.
The move comes after 7 months positive chart setup for the $833.74 million company. It was reported on Sep, 17 by Barchart.com. We have $16.02 PT which if reached, will make NASDAQ:HRTX worth $33.35 million more.

Analysts expect Heron Therapeutics Inc (NASDAQ:HRTX) to report $-0.87 EPS on November, 14.They anticipate $0.37 EPS change or 29.84 % from last quarter’s $-1.24 EPS. After having $-0.80 EPS previously, Heron Therapeutics Inc’s analysts see 8.75 % EPS growth.

Heron Therapeutics Inc (NASDAQ:HRTX) Ratings Coverage

Among 10 analysts covering Heron Therapeutics (NASDAQ:HRTX), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics had 19 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) earned “Buy” rating by Jefferies on Thursday, July 13. The rating was maintained by Cantor Fitzgerald on Friday, August 18 with “Buy”. The rating was initiated by Lake Street on Thursday, December 10 with “Buy”. Jefferies maintained the shares of HRTX in report on Monday, June 12 with “Buy” rating. The rating was maintained by Cowen & Co with “Buy” on Friday, May 26. Noble Financial maintained Heron Therapeutics Inc (NASDAQ:HRTX) on Thursday, August 10 with “Buy” rating. The firm has “Buy” rating by Cowen & Co given on Thursday, August 3. The company was maintained on Tuesday, August 15 by Jefferies. Aegis Capital maintained Heron Therapeutics Inc (NASDAQ:HRTX) on Thursday, June 1 with “Buy” rating. Aegis Capital initiated the stock with “Buy” rating in Wednesday, October 26 report.

More notable recent Heron Therapeutics Inc (NASDAQ:HRTX) news were published by: Businesswire.com which released: “Heron Therapeutics Reports Financial Results for the Three and Six Months …” on August 09, 2017, also Seekingalpha.com with their article: “Heron Therapeutics: Giving A ‘Thumbs Up’ To This ~$14 Biopharma Stock” published on February 27, 2017, Seekingalpha.com published: “Heron Therapeutics Shows Potential In The Chemotherapy-Induced-Nausea Market” on July 10, 2017. More interesting news about Heron Therapeutics Inc (NASDAQ:HRTX) were released by: Reuters.com and their article: “BRIEF-Heron Therapeutics appoints Robert Hoffman as CFO” published on April 24, 2017 as well as Seekingalpha.com‘s news article titled: “Heron Therapeutics: CINV Franchise Provides Valuation Floor, Significant …” with publication date: February 04, 2017.

Heron Therapeutics, Inc. is a biotechnology firm engaged in developing pharmaceutical products for patients suffering from cancer or pain. The company has market cap of $833.74 million. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. It currently has negative earnings. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: